CL2017001375A1 - Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. - Google Patents
Métodos de monitoreo terapéutico de profármacos de ácido fenilacético.Info
- Publication number
- CL2017001375A1 CL2017001375A1 CL2017001375A CL2017001375A CL2017001375A1 CL 2017001375 A1 CL2017001375 A1 CL 2017001375A1 CL 2017001375 A CL2017001375 A CL 2017001375A CL 2017001375 A CL2017001375 A CL 2017001375A CL 2017001375 A1 CL2017001375 A1 CL 2017001375A1
- Authority
- CL
- Chile
- Prior art keywords
- faa
- hpn
- prodrugs
- methods
- phenylacetic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE AL USA DE GLICERIL TRI-[4-FENILBUTIRATO] (HPN-100), PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR UNA CONDICIÓN SELECCIONADA A PARTIR DEL GRUPO QUE CONSISTE DE CÁNCER, UNA ENFERMEDAD NEURODEGENERATIVAS, UN TRASTORNO METABÓLICO, Y ENFERMEDAD DE CÉLULAS FALCIFORMES PARA LA CUAL EL USO DE GLICERIL TRI-[4-FENILBUTIRATO] (HPN-100) SE ESPERA SEA BENÉFICA EN UN SUJETO, QUE POSEE UNA RELACIÓN EN PLASMA DE FAA (ÁCIDO FENILACÉTICO): PAGN (FENILACETILGLUTAMINA) MENOR A 1. DONDE SE AJUSTA LA DOSIFICACIÓN DE PROFÁRMACO DE PAAS (POR EJEMPLO. HPN-100, PBA) CON BASE EN LA MEDICIÓN DE FAA Y PAGN EN PLASMA Y CALCULAR LA RELACIÓN DE FAA: PAGN PARA ASÍ DETERMINAR SI LA CONVERSIÓN DE FAA A PAGN ES SATURADA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001375A1 true CL2017001375A1 (es) | 2018-01-05 |
Family
ID=49380684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002807A CL2014002807A1 (es) | 2012-04-20 | 2014-10-17 | Metodos de monitoreo terapeutico de profarmacos de acido fenilacetico; metodos para tratar un tratornono de retencion de nitrogeno en un sujeto. |
| CL2017001375A CL2017001375A1 (es) | 2012-04-20 | 2017-05-30 | Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002807A CL2014002807A1 (es) | 2012-04-20 | 2014-10-17 | Metodos de monitoreo terapeutico de profarmacos de acido fenilacetico; metodos para tratar un tratornono de retencion de nitrogeno en un sujeto. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (es) |
| EP (2) | EP3222275B1 (es) |
| JP (3) | JP6234436B2 (es) |
| KR (2) | KR20150013170A (es) |
| CN (3) | CN104540507A (es) |
| AU (3) | AU2012377389A1 (es) |
| BR (1) | BR112014026138A2 (es) |
| CL (2) | CL2014002807A1 (es) |
| CY (1) | CY1118838T1 (es) |
| DK (1) | DK2846791T3 (es) |
| EC (1) | ECSP14024561A (es) |
| ES (2) | ES2807951T3 (es) |
| HR (1) | HRP20170651T1 (es) |
| HU (1) | HUE032726T2 (es) |
| IL (2) | IL235127A (es) |
| LT (1) | LT2846791T (es) |
| MX (1) | MX365302B (es) |
| PL (1) | PL2846791T3 (es) |
| PT (1) | PT2846791T (es) |
| RS (1) | RS55870B1 (es) |
| SG (2) | SG11201406745VA (es) |
| SI (1) | SI2846791T1 (es) |
| SM (1) | SMT201700219T1 (es) |
| WO (1) | WO2013158145A1 (es) |
| ZA (1) | ZA201407597B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| PT2846791T (pt) * | 2012-04-20 | 2017-05-25 | Horizon Therapeutics Llc | Métodos de monitorização terapêutica de profármacos de ácido fenilacético |
| PT2922576T (pt) * | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
| HUE045106T2 (hu) | 2013-10-14 | 2019-12-30 | Immedica Pharma Ab | Eljárások a karbamidciklus rendellenességeinek kezelésére |
| US20170087113A1 (en) * | 2014-06-04 | 2017-03-30 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) * | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| DE69612755T2 (de) | 1995-02-07 | 2001-08-23 | Brusilow Enterprises, Llc | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| SI2153870T1 (sl) | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| WO2009087474A2 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| WO2009134460A1 (en) | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
| WO2010025303A1 (en) * | 2008-08-29 | 2010-03-04 | Hyperion Therapeutics | Dosing and monitoring patients on nitrogen-scavenging drugs |
| ES2695534T3 (es) * | 2008-08-29 | 2019-01-08 | Horizon Therapeutics Llc | Métodos de tratamiento usando fármacos de captación de amoniaco |
| CN102481271A (zh) * | 2009-05-11 | 2012-05-30 | 博格生物系统有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法 |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| WO2012028620A1 (en) | 2010-08-31 | 2012-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| EP3263102A1 (en) * | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| PT2846791T (pt) * | 2012-04-20 | 2017-05-25 | Horizon Therapeutics Llc | Métodos de monitorização terapêutica de profármacos de ácido fenilacético |
| PT2922576T (pt) | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
-
2012
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001375A1 (es) | Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| NZ720885A (en) | Rna transcription vector and uses thereof | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| SI3363433T1 (sl) | Metode za zmanjševanje tveganja kardiovaskularnega dogodka pri subjektu, ki prejema zdravljenje s statini, z uporabo etil estra eikozapentaenojske kisline | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| MX2020001262A (es) | Compuestos de platino a base de lipido y nanoparticulas. | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| PH12015500252A1 (en) | Niclosamide for the treatment of solid tumors | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| SG11201605159UA (en) | Processes to improve reactor stability for the preparation of ethylene-based polymers using asymmetrical polyenes | |
| MX2015014344A (es) | Terapia contra el cancer. | |
| MX2013013891A (es) | Sistema y metodo de tratamiento de agua anti-incrustaciones. | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| CU24499B1 (es) | Proceso para preparar ésteres de ácido láctico y ácido 2-hidroxi-3-butenoico a partir de azúcares | |
| BR112016008895A8 (pt) | métodos para formação de compostos homoalílicos pela reação de precursores de ciclopropilvinila com ácido de bronsted, e para formação de ambrox | |
| BR112015030431A2 (pt) | formulação de liberação modificada | |
| MX394430B (es) | Proceso para la preparación de 5-fluoro-1h-pirazoles. | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| UA119441C2 (uk) | Посилювачі водорозчинності на основі глікогену | |
| BR112015013106A2 (pt) | uso de extrato de feno-grego para melhorar a libido feminina | |
| TN2017000174A1 (en) | Low dosage a2a antagonist for the treatment of adhd and parkinsons |